New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
04:55 EDTSIAL, SIAL, SIAL, MMS, MMS, MMS, MD, MD, MD, MASI, MASI, MASI, LPNT, LPNT, LPNT, STE, STE, STE, XRAY, XRAY, XRAY, MRK, MRK, MRK, JNJ, JNJ, JNJCitigroup to host a conference
Global Healthcare Conference is being held in New York on February 24-26.
News For SIAL;MMS;MD;MASI;LPNT;STE;XRAY;MRK;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 15, 2015
07:35 EDTJNJMedivation price target raised to $148 from $128 at Leerink
Subscribe for More Information
May 14, 2015
14:54 EDTJNJJohnson & Johnson unit reports results of VENTURE-AF trial
Subscribe for More Information
13:02 EDTLPNTLifePoint and Watertown Regional Medical Center agrees to partnership
Subscribe for More Information
09:41 EDTJNJLeerink medical devices analyst holds a cardiology luncheon meeting
Subscribe for More Information
09:22 EDTMRKLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:24 EDTMASIMasimo says protocol using Masimo PVI led to significant reductions in LOS
Subscribe for More Information
08:02 EDTLPNTHealthcare Facilities sector upgraded to Attractive at Morgan Stanley
Subscribe for More Information
May 13, 2015
18:33 EDTMRKMerck to present new Keytruda data on 10 types of cancer at 2015 ASCO meeting
Subscribe for More Information
17:50 EDTJNJPharmacyclics to showcase new 'promising' Imbruvica data at ASCO
Pharmacyclics announced that ibrutinib, also known as Imbruvica, single-agent and combination data will be featured in seven oral and poster sessions at the 51st American Society of Clinical Oncology, ASCO, Annual Meeting being held May 29-June 2 in Chicago, IL. According to a statement from ASCO, Imbruvica data will also be included in the official press program during the meeting for the second time in two years. Imbruvica is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a Johnson & Johnson (JNJ) subsidiary. Data being presented include, among others, an oral presentation from the Phase III HELIOS study of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia, a poster presentation of ibrutinib in steroid-dependent or refractory chronic graft-versus-host-disease as well as a dose adherence analysis of ibrutinib 420 mg administered to previously treated CLL patients. "We look forward to sharing promising data at this year's ASCO that examines the use of Imbruvica across a broad range of hematologic disease settings from our clinical studies," said Danelle James, M.D., M.S., Head of Oncology at Pharmacyclics.
13:12 EDTMRKSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
May 12, 2015
13:13 EDTMRKExpert says Norway biosimilar case an 'outlier,' CT Financial News reports
Subscribe for More Information
08:42 EDTMDMEDNAX to acquire vRad in cash transaction valued at $500M
Subscribe for More Information
07:35 EDTMDMEDNAX to host conference call
Conference call to discuss acquisition of vRad will be held on May 12 at 9 am. Webcast Link
07:11 EDTMDMEDNAX to acquire vRad for $500M in cash
MEDNAX announced the signing of a definitive agreement to acquire Virtual Radiologic Corporation, or vRad, a radiology physician services and telemedicine company, for $500M. vRad currently generates annual revenue of roughly $185M through its network of more than 350 U.S.-board certified and eligible radiologists, more than 75% of whom are subspecialty trained. vRadís current management team will remain with the company as part of MEDNAX. The transaction is expected to be completed during the second quarter of 2015. This is a cash transaction, and it is expected to be accretive to earnings, including interest and non-cash amortization expense.
07:09 EDTSIALSigma-Aldrich expands facility in Carlsbad
Sigma-Aldrich Corporation custom manufacturing business unit, SAFC Commercial, announced the strategic expansion of its existing facility in Carlsbad, Calif. The investment will further enable SAFC to offer clinical and commercial bulk drug production, as well as fill/finish of viral products for its gene therapy, viral vaccine and immunotherapy customers.
07:08 EDTSIALSigma-Aldrich business completes expansion of St. Louis facility
Sigma-Aldrich announced that SAFC Commercial, its custom manufacturing services business unit, has completed the expansion of its St. Louis facility to support commercial-scale antibody drug conjugate manufacturing. The facility is in final validation and expected to go online as planned in the third quarter of 2015. Once validated, customers will benefit from working with a single supplier from discovery to commercialization.
06:09 EDTMRKThreshold announces Merck receives FDA Fast Track designation for evofosfamide
Subscribe for More Information
May 11, 2015
17:58 EDTJNJJ&J's Janssen gets complete response letter regarding sNDA for Invega Sustenna
Subscribe for More Information
07:12 EDTLPNTLifePoint Hospitals becomes LifePoint Health
Subscribe for More Information
06:37 EDTMASIMasimo management to meet with Roth Capital
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use